高级检索
当前位置: 首页 > 详情页

IL-23 enhances the malignant properties of hepatoma cells by attenuation of HNF4a

文献详情

资源类型:
Pubmed体系:
单位: [a]Department of Immunology, School of Basic Medicine,Tongji Medical College, Huazhong University of Science and Technology, Wuhan,Hubei, China [b]Department of Allergy,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,Hubei, China [c]Department of Infectious Disease, Institute of Infectious Disease,Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan,Hubei, China
出处:

关键词: HBV Hepatocyte nuclear factor 4a IL-23 Tumor progression

摘要:
Chronic infection with hepatitis B virus (HBV) is one of the major risk factors for hepatocellular carcinoma. HBV infection can induce the expression of IL-23. However, the effects of IL-23 on carcinogenesis are rare and contradictory. To investigate the potential role of IL-23 on malignant properties of hepatoma cells, in the present study, first, we confirmed that HBV drove infected hepatoma cells to produce more IL-23. And then we found that at low concentration, human recombinant IL-23 (hrIL-23) enhanced malignant properties of hepatoma cells through increasing the proportion of stem/progenitor cells, promoting proliferation and colony formation, reducing apoptosis and inducing motility and invasivity of them. Hepatocyte nuclear factor 4 alpha (HNF4a), which is essential for liver development and hepatocyte function, was found to be downregulated in HBV integrated or transiently transfected hepatoma cells. Its expression was also decreased in cells treated by hrIL-23 or by HepG2.215 culture supernatant and this decrease could be abolished by supplementation of anti-IL-23p19 antibody. Hence, it is speculated that HBV related IL-23 can enhance malignant properties of hepatoma cells through attenuation of HNF4a. The findings identified a potential target of interventional strategies for treating hepatitis B patients through manipulation of the IL-23. ©Jiang et al.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学 3 区 细胞生物学
最新[2025]版:
第一作者:
第一作者单位: [a]Department of Immunology, School of Basic Medicine,Tongji Medical College, Huazhong University of Science and Technology, Wuhan,Hubei, China [b]Department of Allergy,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,Hubei, China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:630 今日访问量:0 总访问量:457 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)